Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 5:57 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 565 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: System; Lupus Erythematosus Clear all

Conditions: Systemic Lupus Erythematosus, Active Cutaneous Lupus Erythematosus
Interventions: BIIB059 (litifilimab), Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 53
States / cities: Anniston, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 44 more

Conditions: Childhood-onset Systemic Lupus Erythematous, ANCA-Associated Vasculitis (AAV), Juvenile Myasthenia Gravis, Juvenile Dermatomyositis
Interventions: Descartes-08; Drug
Lead sponsor: Cartesian Therapeutics; Industry
Eligibility: 12 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • St Louis, Missouri • Cincinnati, Ohio

Conditions: Systemic Lupus Erythematosus
Interventions: DZP, Placebo; Drug · Other
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 16 Years and older
Enrollment: 321 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 60
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 53 more

Conditions: Systemic Lupus Erythematosus
Interventions: Mycophenolate Mofetil, Placebo for Mycophenolate Mofetil, Voclosporin, Placebo for Voclosporin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 10
States / cities: Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 6 more

Conditions: SLE (Systemic Lupus)
Interventions: Not listed
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Systemic Lupus Erythematosus
Interventions: CEP-33457; Drug
Lead sponsor: Cephalon, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 39
States / cities: Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 33 more

Conditions: Lupus Nephritis (LN)
Interventions: Dapagliflozin (10Mg Tab) along with standard medical therapy, Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 70 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Systemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus Erythematosus
Interventions: Anifrolumab, Anifrolumab; Combination Product · Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 5 Years to 80 Years
Enrollment: 1,072 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 21
States / cities: Phoenix, Arizona • Irvine, California • Los Angeles, California + 18 more

Conditions: Discoid Lupus Erythematosus, Systemic Lupus Erythematosus
Interventions: Tofacitinib citrate; Biological
Lead sponsor: Tufts Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Systemic Lupus Erythematosus
Interventions: TRU-015; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 6
States / cities: Los Angeles, California • Palo Alto, California • Lake Success, New York + 3 more

Conditions: Systemic Lupus Erythematosus
Interventions: BI 3000202, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 405 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 30
States / cities: Beverly Hills, California • La Palma, California • San Diego, California + 27 more

Conditions: Systemic Lupus Erythematosus
Interventions: Ortho-Novum 777; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 39 Years · Female only
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2003
U.S. locations: 15
States / cities: Los Angeles, California • Chicago, Illinois • Shreveport, Louisiana + 11 more

Conditions: Systemic Lupus Erythematosus
Interventions: Deucravacitinib, Placebo; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 516 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 48
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 42 more

Conditions: Systemic Lupus Erythematosus
Interventions: Blood Collection; Other
Lead sponsor: CorEvitas; Network
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2099
U.S. locations: 1
States / cities: Waltham, Massachusetts

Conditions: Lupus Erythematosus, Systemic
Interventions: Placebo, MEDI-570 0.03 MG, MEDI-570 0.1 MG, MEDI-570 0.3 MG, MEDI-570 1 MG; Other · Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 9
States / cities: Long Beach, California • San Leandro, California • Fort Lauderdale, Florida + 6 more

Conditions: Systemic Lupus Erythematosus
Interventions: GSK4527363, Placebo matching GSK4527363, Belimumab; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 143 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 2
States / cities: Las Vegas, Nevada • Columbus, Ohio

Conditions: Lupus
Interventions: BMS-931699, Placebo matching BMS-931699; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 730 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 25
States / cities: Huntsville, Alabama • Fullerton, California • Long Beach, California + 22 more

Conditions: Systemic Lupus Erythematosus, SLE, Lupus
Interventions: Vitamin D3, Vitamin D3 placebo; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 8
States / cities: Birmingham, Alabama • San Francisco, California • Boston, Massachusetts + 5 more

Conditions: Systemic Lupus Erythematosus
Interventions: Anifrolumab; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: Female only
Enrollment: 442 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: Wilmington, North Carolina

Conditions: Systemic Lupus Erythematosus
Interventions: non-interventional; Other
Lead sponsor: XDx; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 11
States / cities: Los Angeles, California • San Leandro, California • Atlanta, Georgia + 7 more

Conditions: Systemic Lupus Erythematosus
Interventions: Low Dietary Sodium, High Dietary Sodium; Dietary Supplement
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Systemic Lupus Erythematosus
Interventions: Baricitinib, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 314 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 27
States / cities: Tucson, Arizona • Beverly Hills, California • Covina, California + 22 more

Conditions: Systemic Lupus Erythematosus
Interventions: GSK2586184 standard formulation, Simvastatin, Rosuvastatin, GSK2586184 new formulation; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Lupus Nephritis
Interventions: Daratumumab; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Search by objective public record fields.

Study to Evaluate BIIB059 (Litifilimab) in Cutaneous Lupus Erythematosus (CLE) With or Without Systemic Lupus Erythematosus (SLE)

Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders

A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

Examining Distinct Immunophenotypes to Validate and Enhance Rational Treatment in Systemic Lupus

Evaluation of Patients With Lupus Nephritis Using Kidney MRI (Magnetic Resonance Imaging)

A Long-Term Study of the Safety and Tolerability of Repeated Administration of CEP-33457 in Participants With Systemic Lupus Erythematosus

Dapagliflozin in Active Lupus Nephritis

Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment

Oral Tofacitinib in Adult Subjects With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE)

Study of TRU-015 in Subjects With Membranous Nephropathy Secondary to Systemic Lupus Erythematosus

A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)

Safety of Estrogens in Lupus: Birth Control Pills

A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)

CorEvitas Systemic Lupus Erythematosus (SLE) Drug Safety and Effectiveness Registry

A Safety and Tolerability Study of MEDI-570 in Systemic Lupus Erythematosus

A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD Participants

Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus

Vitamin D3 in Systemic Lupus Erythematosus

Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users

The Systemic Lupus Erythematosus (SLE) Activity Gene Expression (SAGE) Study

Tissue Sodium in Autoimmune Disease

A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)

A Two-part Study to Investigate the Interaction and Pharmacokinetics of GSK2586184

Daratumumab to Treat Active Lupus Nephritis